Findings

What do systematic reviews say?

192 questions · 196 findings · 89 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 15.8%GRADE not reported 18 · 9.2%Very low 68 · 34.7%Low 48 · 24.5%Moderate 24 · 12.2%High 7 · 3.6%

Gabapentin vs placebo

Withdrawals due to adverse events · adults with fibromyalgia

1 finding from 1 review

Gabapentin for fibromyalgia pain in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Very low

Amitriptyline vs placebo

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

Citalopram vs placebo

Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Very low

Amitriptyline vs gabapentin

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Pregabalin vs placebo

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Gabapentin vs amitriptyline

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low

Celecoxib vs naproxen

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 242 participants
Very low

Rofecoxib vs naproxen

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 310 participants
Very low

Meloxicam vs naproxen

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 225 participants
Very low

Anti‐TB therapy vs placebo

Withdrawals due to adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Anti‐tuberculous therapy for maintenance of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.29 [0.6, 2.77]
4 studies · 322 participants
Very low

Azathioprine vs infliximab

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.47 [0.96, 2.23]
1 study · 324 participants
Moderate

Azathioprine + infliximab vs infliximab

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.16 [0.75, 1.8]
1 study · 342 participants
Moderate

Azathioprine or 6‐mercaptopurine vs methotrexate

Withdrawals due to adverse events · Patients with active Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.78 [0.23, 2.71]
2 studies · 85 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐ASA or Sulfasalzine

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.98 [0.38, 2.54]
2 studies · 156 participants
Low

Azathioprine or 6‐mercaptopurine vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.7 [0.94, 3.08]
8 studies · 510 participants
Moderate

Bisphosphonates vs control

Withdrawals due to adverse events · adults with GIOP

Bisphosphonates showed no clear difference in withdrawals due to adverse events compared with control (low certainty).

1 finding from 1 review

Bisphosphonates for steroid‐induced osteoporosis 2016 · Cochrane Headline outcomes only
RR 1.06 [0.77, 1.47]
15 studies · 1790 participants
Low

5‐ASA vs placebo

Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.11 [0.88, 1.38]
10 studies · 1833 participants
Low

Fingolimod 0.5 mg vs interferon beta‐1a

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.51 [0.81, 2.8]
1 study · 860 participants
Moderate

Fingolimod 0.5 mg vs placebo

Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis

It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.42 [0.89, 2.25]
2 studies · 1556 participants
Very low

Oxycodone MR vs placebo

Withdrawals due to adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

1 finding from 1 review

Oxycodone for neuropathic pain in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 680 participants
Very low